Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 1/2017

01-02-2017 | Invited Review Article

One-step nucleic acid amplification (OSNA): where do we go with it?

Author: Yasuhiro Tamaki

Published in: International Journal of Clinical Oncology | Issue 1/2017

Login to get access

Abstract

The one-step nucleic acid amplification (OSNA) assay was initially developed for the intraoperative assessment of sentinel lymph node metastases in breast cancer. This assay measures cytokeratin 19 (CK19) mRNA copy number and is widely used in hospitals. The results of the IBCSG 23-01, ACOSOG Z0011, and AMAROS trials demonstrated that no further axillary dissection is required for patients with sentinel lymph nodes that tested positive for cancer, which has led to a decreasing trend in the need for intraoperative assessment of lymph nodes. Here, I review studies relevant to OSNA and discuss perspectives on future applications of OSNA in cancer surgery. The studies reviewed were identified by carrying out a search on PubMed for all articles pertaining to OSNA and published prior to the end of June 2016 using the keywords “OSNA” or “one-step nucleic acid amplification” in the title or abstract. Method comparison studies between OSNA and pathological assessment for the detection of lymph node metastasis in breast cancer revealed that in a pooled assessment OSNA had a high specificity (94.8 %), high concordant rate (93.8 %), and a negative predictive value (97.6 %). Similar results have been found for gastric, colorectal, and lung cancers in multicenter studies. These results demonstrate that OSNA can serve as an alternative method to pathological assessment for examining lymph node metastasis. Multicenter prospective studies with a large sample size are needed to definitively reveal the superiority of OSNA over pathological assessment to predict prognosis. Technical refinements to improve the assay are essential to its further development as a new standard for testing in place of pathological examination.
Literature
1.
Giuliano AE, Hunt KK, Ballman KV et al (2011) Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305:569–575CrossRefPubMed
2.
Galimberti V, Cole BF, Zurrida S et al (2013) Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a randomized controlled trial. Lancet Oncol 14:297–305CrossRefPubMedPubMedCentral
3.
Donker M, van Tienhoven G, Straver ME et al (2014) Radiotherapy of surgery of the axillar after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomized, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol 15:1303–1310CrossRefPubMedPubMedCentral
4.
Veronesi U, Giovanni P, Giuseppe V et al (1999) Sentinel lymph node biopsy and axillary dissection in breast cancer: a results in a large series. J Natl Cancer Inst 91:368–373CrossRefPubMed
5.
Tsujimoto M, Nakabayashi K, Yoshidome K (2007) One-step nucleic acid amplification for intraoperative detection of lymph node metastasis in breast cancer patients. Clin Cancer Res 13:4807–4816CrossRefPubMed
6.
Visser M, Jiwa M, Horstman A et al (2008) Intraoperative rapid diagnostic method based on CK19 mRNA expression for detection of lymph node metastases in breast cancer. Int J Cancer 122:2562–2567CrossRefPubMedPubMedCentral
7.
Schem C, Maass N, Bauerschlag DO et al (2009) One-step nucleic acid amplification—a molecular method for the detection of lymph node metastases in breast cancer patients; results of the German study group. Virchow Arch 454:203–210CrossRef
8.
Tamaki Y, Akiyama F, Iwase T et al (2009) Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 15:2879–2884CrossRefPubMed
9.
Feldman S, Krishnamurthy S, Gillanders W et al (2011) A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer 117:2599–2607CrossRefPubMedPubMedCentral
10.
Khaddage A, Berremila SA, Forest F et al (2011) Implementation of molecular intra-operative assessment of sentinel lymph node in breast cancer. Anticancer Res 31:585–590PubMed
11.
Bernet L, Cano R, Martinez M et al (2011) Diagnosis of the sentinel lymph node in breast cancer: a reproducible molecular method: a multicentric Spanish study. Histopathology 58:863–869CrossRefPubMed
12.
Snook KL, Layer GT, Jackson PA et al (2011) Multicentre evaluation of intraoperative molecular analysis of sentinel lymph nodes in breast carcinoma. Br J Surg 98:527–535CrossRefPubMed
13.
Le Frère-Belda MA, Bats AS, Gillaizeau F et al (2012) Diagnostic performance of one-step nucleic acid amplification for intraoperative sentinel node metastasis detection in breast cancer patients. Int J Cancer 130:2377–2386CrossRefPubMed
14.
Wang YS, Ou-ynag T, Wu J et al (2012) Comparative study of one-step nucleic acid amplification assay, frozen section, and touch imprint cytology for intraoperative assessment of breast sentinel lymph node in Chinese patients. Cancer Sci 103:1189–1193CrossRef
15.
Sagara Y, Ohi Y, Matsukata A et al (2013) Clinical application of the one-step nucleic acid amplification method to detect sentinel lymph node metastasis in breast cancer. Breast Cancer 20:181–186CrossRefPubMed
16.
Buglioni S, Di Filippo F, Terrenato I et al (2013) Quantitative molecular analysis of sentinel lymph node may be predictive of axillary node status in breast cancer classified by molecular subtypes. PLoS One 8:e58823CrossRefPubMedPubMedCentral
17.
Smolarz B, Krawczky T, Westfal B et al (2013) Comparison of one-step nucleic acid amplification (OSNA) method and routine histological investigation for intraoperative detection of lymph node metastasis in Polish women with breast cancer. Pol J Pathol 64:104–108CrossRefPubMed
18.
Banerjee SM, Michalopoulos NV, Williams NR et al (2014) Detailed evaluation of one-step nucleic acid (OSNA) molecular assay for intraoperative diagnosis of sentinel lymph node metastasis and prediction of non-sentinel nodal involvement: experience from a London Teaching Hospital. Breast 23:378–384CrossRefPubMed
19.
Pathmanathan N, Renthawa J, French JR et al (2014) Intraoperative sentinel lymph node assessment in breast cancer: a comparison of rapid diagnostic method on CK19 mRNA expression and imprint cytology. ANZ J Surg 84:730–734CrossRefPubMed
20.
Chaudhry A, Williams S, Cook J et al (2014) The real-time intra-operative evaluation of sentinel lymph nodes in breast cancer patients using one step nucleic acid amplification (OSNA) and implications for clinical decision-making. Eur J Surg Oncol 40:150–157CrossRefPubMed
21.
Li D, Xu X, Chen J et al (2015) Utility of one-step nucleic acid amplification (OSNA) assay in detecting breast cancer metastases of sentinel lymph nodes in a Chinese population. Breast Cancer 22:135–140CrossRefPubMed
22.
Tamaki Y, Sato N, Homma K et al (2012) Routine clinical use of the one-step nucleic acid amplification assay for detection of sentinel lymph node metastases in breast cancer patients: results of a multicenter study in Japan. Cancer 118:3477–3488CrossRefPubMed
23.
Godey F, Leveque J, Tas P et al (2012) Sentinel lymph node analysis in breast cancer: contribution of one-step nucleic acid amplification (OSNA). Breast Cancer Res Treat 131:509–516CrossRefPubMed
24.
Ohi Y, Umekita Y, Sagara Y et al (2012) Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breast cancer. Br J Cancer 107:1239–1243CrossRefPubMedPubMedCentral
25.
Castellano I, Macri L, Deambrogio C et al (2012) Reliability of whole sentinel lymph node analysis by one-step nucleic acid amplification for intraoperative diagnosis of breast cancer metastasis. Ann Surg 255:334–342CrossRefPubMed
26.
Heilmann T, Mathiak M, Hofmann J et al (2013) Intra-operative use of one-step nucleic acid amplification (OSNA) for detection of the tumor load of sentinel lymph nodes in breast cancer patients. J Cancer Res Clin Oncol 139:1649–1655CrossRefPubMed
27.
Remoundos DD, Ng VV, Wilson HA et al (2013) The use of one step nucleic-acid amplification (OSNA) in clinical practice: a single-centre study. Breast 22:162–167CrossRefPubMed
28.
Babar M, Madani R, Thwaites L et al (2014) A differential intra-operative molecular biological test for the detection of sentinel lymph node metastases in breast carcinoma. An extended experience from the first UK centre routinely offering the service in clinical practice. Eur J Surg Oncol 40:282–288CrossRefPubMed
29.
Babar M, Madani R, Jackson P et al (2016) One step nucleic acid amplification (OSNA) positive micrometastases and additional histopathological NSLN metastases: results from a single institute over 53 months. Surgeon 14:76–81CrossRefPubMed
30.
Kubota M, Komoike Y, Hamada M et al (2016) One-step nucleic acid amplification assay for intraoperative prediction of advanced axillary lymph node metastases in breast cancer patients with sentinel lymph node metastasis. Mol Clin Oncol 4:173–178PubMed
31.
Banerjee SM, Michalopoulos NV, Williams NR et al (2014) Detailed evaluation of one step nucleic acid (OSNA) molecular assay for intra-operative diagnosis of sentinel lymph node metastasis and prediction of non-sentinel nodal involvement: experience from a London teaching hospital. Breast 23:378–384CrossRefPubMed
32.
Deambrogio C, Castellano I, Paganotti A et al (2014) A new clinical cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node better identifies patients eligible for axillary lymph node dissection in breast cancer. J Clin Pathol 67:702–706CrossRefPubMed
33.
Peg V, Espinosa-Bravo M, Vieites B et al (2013) Intraoperative molecular analysis of total tumor load in sentinel lymph node: a new predictor of axillary status in early breast cancer patients. Breast Cancer Res Treat 139(87):87–93CrossRefPubMed
34.
Rubio IT, Espinosa-Bravo M, Rodringo M et al (2014) Nomogram including the total tumoral load in the sentinel nodes assessed by one-step nucleic acid amplification as a new factor for predicting nonsentinel lymph node metastasis in breast cancer patients. Breast Cancer Res Treat 147:371–380CrossRefPubMed
35.
Teramoto A, Shimazu K, Naoi Y et al (2014) One-step nucleic acid amplification assay for intraoperative prediction of non-sentinel lymph node metastasis in breast cancer patients with sentinel lymph node metastasis. Breast 23:579–585CrossRefPubMed
36.
37.
Osako T, Tsuda H, Horii R et al (2013) Molecular detection of lymph node metastasis in breast cancer patients treated with preoperative systemic chemotherapy: a prospective multicenter trial using the one-step nucleic acid amplification assay. Br J Cancer 109:1693–1698CrossRefPubMedPubMedCentral
38.
Takamoto K, Shimazu K, Naoi Y et al (2016) One-step nucleic acid amplification assay for detection of axillary lymph node metastases in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 23:78–86CrossRefPubMed
39.
Vietes B, López-Garcia MA, Castilla C et al (2015) CK19 expression in breast tumors and lymph node metastasis after neoadjuvant therapy. Histopatholgy 9(2):239–249
40.
Yaguchi Y, Sugasawa H, Tsujimoto H et al (2011) One-step nucleic acid amplification (OSNA) for the application of sentinel node concept in gastric cancer. Ann Surg Oncol 18:2289–2296CrossRefPubMed
41.
Kumagai K, Yamamoto N, Miyashiro I et al (2014) Multicenter study evaluating the clinical performance of the OSNA assay for the molecular detection of lymph node metastases in gastric cancer patients. Gastric Cancer 17:273–280CrossRefPubMed
42.
Croner RS, Geppert CI, Bader FG et al (2014) Molecular staging of lymph node-negative colon carcinomas by one-step nucleic acid amplification (OSNA) results in upstaging of a quarter of patients in a prospective, European, multicenter study. Br J Cancer 110:2544–2550CrossRefPubMedPubMedCentral
43.
Yamamoto H, Sekimoto M, Oya M et al (2011) OSNA-based novel molecular testing for lymph node metastases in colorectal cancer patients: results from a multicenter clinical performance study in Japan. Ann Surg Oncol 18:1891–1898CrossRefPubMed
44.
Güller U, Zettl A, Worni M et al (2012) Molecular investigation of lymph nodes in colon cancer patients using one-step nucleic acid amplification (OSNA): a new road to better staging? Cancer 118:6039–6045CrossRefPubMedPubMedCentral
45.
Yamamoto H, Tomita N, Inomata M et al (2016) OSNA-assisted molecular staging in colorectal cancer: a prospective multicenter trial in Japan. Ann Surg Oncol 23:391–396CrossRefPubMed
46.
Inoue M, Hiyama K, Nakabayashi K et al (2012) An accurate and rapid detection of lymph node metastasis in non-small cell lung cancer patients based on one-step nucleic acid amplification assay. Lung Cancer 78:212–218CrossRefPubMed
47.
Hayama M, Chida M, Karube Y et al (2014) One-step nucleic acid amplification for detection of lymph node metastasis in lung cancer. Ann Thorac Cardiovasc Surg 20:181–184CrossRefPubMed
48.
Nakagawa K, Asamura H, Tsuta K et al (2016) The novel one-step nucleic acid amplification (OSNA) assay for the diagnosis of lymph node metastasis in patients with non-small cell lung cancer (NSCLC): results of a multicenter prospective study. Lung Cancer 97:1–7
49.
Kaczka K, Fendler W, Borowiec M et al (2014) First one-step nucleic acid amplification testing in papillary thyroid cancer lymph nodes—a comparison with histopathology and real-time PCR. Endokrynol Pol 65:422–430CrossRefPubMed
50.
Kaczka K, Fendler W, Borowiec M et al (2015) One-step nucleic acid amplification testing in medullary thyroid carncer lymph nodes: a case series. Arch Med Sci 1:137–141CrossRef
51.
del Carmen S, Gatius S, Franch-Arcas G et al (2016) Concordance study between one-step nucleic acid amplification and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroid. Hum Pathol 48:132–141CrossRefPubMed
52.
Okamoto S, Niikura H, Nakabayashi K et al (2013) Detection of sentinel lymph node metastases in cervical cancer: assessment of KRT19 mRNA in the one-step nucleic acid amplification (OSNA) method. Gynecol Oncol 130:530–536CrossRefPubMed
53.
Nagai T, Niikura H, Okamoto S et al (2015) A new diagnostic method for rapid detection of lymph node metastases using a one-step nucleic acid amplification (OSNA) assay in endometrial cancer. Ann Surg Oncol 22:980–986CrossRefPubMed
54.
Matsuzuka T, Takahashi K, Kawakita D et al (2012) Intraoperative molecular assessment for lymph node metastasis in head and neck squamous cell carcinoma using one-step nucleic acid amplification (OSNA) assay. Ann Surg Oncol 19:3865–3870CrossRefPubMed
55.
Goda H, Nakashiro K, Oka R et al (2012) One-step nucleic acid amplification for detecting lymph node metastasis of head and neck squamous cell carcinoma. Oral Oncol 48:958–963CrossRefPubMed
56.
Cyr AE, Tucker N, Ademuyiwa F et al (2016) Successful completion of the pilot phase of randomized controlled trial comparing sentinel lymph node biopsy to no further axillary staging in patients with clinical T1-2 N0 breast cancer and normal axillary ultrasound. J Am Coll Surg 223(2):399–407CrossRefPubMed
57.
Henry NL, Somerfield MR, Abramson VG et al (2016) Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American Society of Clinical Oncology endorsement of cancer care Ontario guideline recommendations. J Clin Oncol 34:2303–2311CrossRefPubMed
58.
Weaver DL, Krag DN, Manna EA et al (2006) Detection of occult sentinel lymph node micrometastases by immunohistochemistry in breast cancer. An NSABP protocol B-32 assurance study. Cancer 107:661–667CrossRefPubMed
59.
Fisher B, Bauer M, Wickerham DL et al (1983) Relation of positive axillary nodes to prognosis of patients with primary breast cancer. An NSABP update. Cancer 52:1551–1557CrossRefPubMed
60.
Kimbrough CW, McMasters KM, Quillo A et al (2015) Occult metastases in node-negative breast cancer: a surveillance, epidemiology, and end results-based analysis. Surgery 158:494–500CrossRefPubMed
61.
Martin-Sánchez E, Pemaut-Leza E, Mendaza S et al (2016) Gene promotor hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA. Virchows Arch 469(1):51–59
Metadata
Title
One-step nucleic acid amplification (OSNA): where do we go with it?
Author
Yasuhiro Tamaki
Publication date
01-02-2017
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 1/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1030-9

Other articles of this Issue 1/2017

International Journal of Clinical Oncology 1/2017 Go to the issue

Original Article

Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy

Original Article

Psychological impact of positive cervical cancer screening results among Japanese women

Original Article

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea

Original Article

Template-based lymphadenectomy reduces the risk of regional lymph node recurrence among patients with upper/middle ureteral cancer

Original Article

Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers

Original Article

The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits